Patents Assigned to Pfizer
  • Patent number: 6448278
    Abstract: Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: September 10, 2002
    Assignee: Pfizer Inc.
    Inventors: Simon Bailey, Stephane Billotte, Andrew Michael Derrick, Paul Vincent Fish, Kim James, Nicholas Murray Thomson
  • Patent number: 6448293
    Abstract: A compound of general formula (I), or pharmaceutically acceptable salts, solvates or polymorphs thereof; wherein; R1 and R2, which may be the same or different, are hydrogen, C1-C6alkyl, (CH2)m (C3-C6cycloalkyl) wherein m =0, 1, 2 or 3, or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; each R3 is independently CF3, OCF3, C1-4alkylthio or C1-C4alkoxy; n is 1, 2 or 3; and R4 and R5, which may be the same or different, are: A—X, wherein A =—CH=CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; R6, R7, R8 and R10 which may be the same or different, are hydrogen or C1-6alkyl optionally substituted independently by one or more R12; R9 is C1-6 alkyl optionally substituted independently by one or more R12; R11 is hydrogen, C1-6 alkyl optionally substituted independently by one or more R12, C(O
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: September 10, 2002
    Assignee: Pfizer Inc.
    Inventors: Mark David Andrews, David Hepworth, Donald Stuart Middleton, Alan Stobie
  • Patent number: 6448236
    Abstract: The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as adenosine A2a receptor agonists.
    Type: Grant
    Filed: October 16, 2000
    Date of Patent: September 10, 2002
    Assignee: Pfizer Inc
    Inventor: Sandra Marina Monaghan
  • Publication number: 20020123520
    Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1
    Type: Application
    Filed: January 31, 2002
    Publication date: September 5, 2002
    Applicant: Pfizer Inc.
    Inventors: Anthony Marfat, Michael William McKechney
  • Publication number: 20020123510
    Abstract: This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a sodium channel antagonist; (b) a nitric oxide synthase (NOS) inhibitor; (c) a glycine site antagonist; (d) a potassium channel opener; (e) an AMPA/ kainate receptor antagonist; (f) a calcium channel antagonist; (g) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); or (h) an antiinflammatory agent. This invention also relates to methods of treating hypoxic or ischemic stroke comprising administering to a patient in need of such treatment an NMDA receptor antagonist in combination with a thrombolytic agent.
    Type: Application
    Filed: September 6, 2001
    Publication date: September 5, 2002
    Applicant: Pfizer Inc.
    Inventors: Bertrand L. Chenard, Frank S. Menniti, Mario D. Saltarelli
  • Publication number: 20020123490
    Abstract: The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.
    Type: Application
    Filed: December 6, 2001
    Publication date: September 5, 2002
    Applicant: Pfizer Inc.
    Inventor: Harry R. Howard
  • Patent number: 6442850
    Abstract: In a shaving razor using a blade cartridge, the reusable assembly of the razor includes a guard element and the blade cartridge is designed with no parts located in front of the blade edge or edges, and when the blade cartridge is installed in the reusable assembly, the guard element of the reusable assembly becomes located in front of the blade edge or edges of the blade cartridge to cooperate with the blade edges in a customary way to stretch the skin and erect the beard hairs in advance of the cutting edge. The blade cartridge is also movable about two different pivot axes to improve the safety of the razor during use.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: September 3, 2002
    Assignee: Pfizer Inc.
    Inventor: David C. Coffin
  • Patent number: 6444826
    Abstract: The invention relates to processes for preparing a compound of the formula and the enantiomer of said compound, wherein the benzoic acid moiety is attached at position 6 or 7 of the chroman ring, and R1, R2, and R3 are as defined herein. The invention further relates to intermediates that are useful in the preparation of the compound of formula X above.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: September 3, 2002
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, Joel M. Hawkins, Stephane Caron, Sarah E. Kelly, Jeffrey W. Raggon, Michael J. Castaldi, Robert W. Dugger, Sally G. Ruggeri
  • Patent number: 6444677
    Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y1 is —(CH2)m—, C(O) or S(O); Y2 is N or CH; R1 and R2 are independently C1-4 alkyl; R3 is selected from the following: (a) optionally substituted —(CH2)p—C3-7 cycloalkyl; (b) optionally substituted —C5-7 alkyl; and (c) substituted —C1-4 alkyl; and (d) optionally substituted C7-9 bicycloalkyl; R4 is optionally substituted thiazolyl, imidazolyl or oxazolyl; X is S, —NH, —N—C1-4 alkyl or O; R5 is hydrogen or C1-4 alkyl; R6 is C1-4 alkyl or halo; m is 0, 1 or 2; n is 0, 1, 2, 3, 4 or S; and p is 0, 1, 2, 3, 4, 5 or 6. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: September 3, 2002
    Assignee: Pfizer Inc.
    Inventors: Takafumi Ikeda, Mitsuhiro Kawamura, Noriaki Murase, Seiji Nukui, Yuji Shishido, Makato Kawai, Yoshiyuki Okumura
  • Patent number: 6444679
    Abstract: The present invention relates to compounds of the formula I, wherein Z1, X, Y, ( )n, R1, R2 and R3 are defined as in the specification, pharmaceutical compositions containing such compounds; and the use of such compounds to treat neurological and gastrointestinal disorders.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: September 3, 2002
    Assignee: Pfizer Inc
    Inventors: Spiros Liras, Stanton F. McHardy
  • Publication number: 20020119961
    Abstract: A compound of the formula 1
    Type: Application
    Filed: October 5, 2001
    Publication date: August 29, 2002
    Applicant: Pfizer Inc.
    Inventors: Laura C. Blumberg, Matthew F. Brown, Ronald P. Gladue, Christopher S. Poss
  • Patent number: 6440709
    Abstract: This invention relates to the isochroman compound of formula (I) and its pharmaceutically acceptable salts, which are useful as an amyloid aggregation inhibitor and for treating Alzheimer's disease. This invention also relates to processes for producing the isochroman compound, which comprises cultivating Penicillium simplicissimum FERM BP-6357 and then isolating the isochroman compound from the fermentation broth. The present invention also relates to a pharmaceutical composition comprising the isochroman compound.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventors: Hideo Hirai, Toshio Ichiba, Hiroko Tonai
  • Patent number: 6441192
    Abstract: The present invention is concerned with the acylation of indoles, specifically the preparation of 3-acylated indoles which may be further treated to provide indoles having an alternative substituent at the 3-position.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventor: Jolyon Francis Perkins
  • Patent number: 6441015
    Abstract: The present invention relates to tetrazole compounds of Formula I, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs. The invention also relates to compositions comprising the tetrazole compounds and to methods of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, and osteoporosis using the tetrazole compounds.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventors: Gary E. Aspnes, Yuan-Ching P. Chiang
  • Patent number: 6441193
    Abstract: Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Paul A. Dasilva-Jardine, Hua Zhu Ke, Robert L. Rosati
  • Patent number: 6441176
    Abstract: Methods of preparing NHE-1 disclosed. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventor: Norma J. Tom
  • Patent number: 6441181
    Abstract: A process is provided for preparing a compound of the formula: using a compound having the formula wherein R2 and R3 are independently C1-C3 alkyl or phenyl.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventor: Robert W. Scott
  • Patent number: 6440982
    Abstract: There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventors: Graham Nigel Maw, David James Rawson
  • Patent number: 6441000
    Abstract: There is provided a compound of formula I, wherein Het1, T, X, R1, R2 and R3 have meanings given in the description, which are useful in the prophylaxis and in the treatment of diseases mediated by opiate receptors, such as pruritus.
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc
    Inventors: Stephen Paul Gibson, Ivan Tommasini, Kimberley Verrier, Lee Roberts, Brian Scott Bronk, Richard Edward Armer
  • Patent number: 6441018
    Abstract: The pyrazoles and pyrazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: August 27, 2002
    Assignee: Pfizer Inc.
    Inventors: William Stephen Faraci, Willard McKowan Welch, Jr.